Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL ...
2017年4月13日 · ORION-1 was a randomized, double-blind, placebo-controlled, phase 2, multicenter trial. The objective was to evaluate the effects of different doses and dosing …
Orion Spacecraft - NASA
2025年3月20日 · NASA’s Orion spacecraft is built to take humans farther into deep space than ever before. Launching atop NASA’s Space Launch System (SLS) rocket, Orion will carry the …
In an ORION-1-like population, inclisiran 300 mg delivers sustained LDL-C lowering of 60-65 mg/dL In a CVOT, this is likely to confer substantial reductions in MACE ORION-4 will study …
LDL-C Reduction From 6 to 9 Months Following Single or Second …
2017年8月28日 · The ORION-1 trial showed that inclisiran was superior to placebo at reducing LDL-C levels. The goal of the trial was to evaluate if inclisiran, which is designed to target …
Orion 1 - Wikipedia
Orion 1 or Orion-1 may refer to: Exploration Flight Test-1, the first test launch of the Orion space capsule in 2014; Orión (rocket), a sounding rocket prototype from Argentina, launched in 1965 …
ORION-1: Sustained LDL-C Reduction With Inclisiran in Phase 2 …
2017年3月10日 · A novel approach to lowering LDL-cholesterol (LDL-C), with the ribonucleic acid (RNA) interference drug inclisiran, provides significant, dose-dependent and sustained …
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein ...
This analysis of the ORION-1 trial extends our prior observations through to 1 year and provides the largest and longest safety data set, to our knowledge, to date for a small interfering RNA in …
What is Orion? - NASA
Orion is NASA’s new spacecraft, built to take humans farther into space than they’ve ever gone before. It will carry the crew to space, provide emergency abort capability, sustain the crew …
ESC 2017 | ORION 1研究：双次注射300 mg PCSK9抑制剂可稳定 …
2017年8月29日 · orion 1试验设计 该研究共纳入497例高风险心血管疾病患者，并随机分配成单次注射治疗组和双次注射治疗组。 每组再随机分为四个亚组，其中单次注射治疗组分别给予安 …
Inclisiran降低糖尿病状态下的LDL-C和PCSK9：ORION-1 ... - X-MOL
目的通过糖尿病状况评估Inclisiran的疗效和安全性。 研究设计与方法ORION-1（ClinicalTrials.gov，NCT02597127）将501名患有动脉粥样硬化性心血管疾病（ASCVD） …